120 related articles for article (PubMed ID: 28270142)
1. Dynamic proteomics reveals bimodal protein dynamics of cancer cells in response to HSP90 inhibitor.
Zimmer A; Amar-Farkash S; Danon T; Alon U
BMC Syst Biol; 2017 Mar; 11(1):33. PubMed ID: 28270142
[TBL] [Abstract][Full Text] [Related]
2. Dynamic proteomics of individual cancer cells in response to a drug.
Cohen AA; Geva-Zatorsky N; Eden E; Frenkel-Morgenstern M; Issaeva I; Sigal A; Milo R; Cohen-Saidon C; Liron Y; Kam Z; Cohen L; Danon T; Perzov N; Alon U
Science; 2008 Dec; 322(5907):1511-6. PubMed ID: 19023046
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
4. Dynamic impacts of the inhibition of the molecular chaperone Hsp90 on the T-cell proteome have implications for anti-cancer therapy.
Fierro-Monti I; Echeverria P; Racle J; Hernandez C; Picard D; Quadroni M
PLoS One; 2013; 8(11):e80425. PubMed ID: 24312219
[TBL] [Abstract][Full Text] [Related]
5. Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration.
Zismanov V; Drucker L; Gottfried M
Anticancer Drugs; 2014 Oct; 25(9):998-1006. PubMed ID: 25153785
[TBL] [Abstract][Full Text] [Related]
6. The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.
Kaufman KL; Jenkins Y; Alomari M; Mirzaei M; Best OG; Pascovici D; Mactier S; Mulligan SP; Haynes PA; Christopherson RI
Oncotarget; 2015 Dec; 6(38):40981-97. PubMed ID: 26556860
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of ERK1/2 and AKT-mediated X-ray repair cross-complement group 1 protein (XRCC1) expression by Hsp90 inhibition enhances the gefitinib-induced cytotoxicity in human lung cancer cells.
Tung CL; Jian YJ; Syu JJ; Wang TJ; Chang PY; Chen CY; Jian YT; Lin YW
Exp Cell Res; 2015 May; 334(1):126-35. PubMed ID: 25662161
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
Ohba S; Hirose Y; Yoshida K; Yazaki T; Kawase T
J Neurosurg; 2010 Jan; 112(1):33-42. PubMed ID: 19408974
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells.
Tung CL; Chiu HC; Jian YJ; Jian YT; Chen CY; Syu JJ; Wo TY; Huang YJ; Tseng SC; Lin YW
Exp Cell Res; 2014 Apr; 322(2):345-54. PubMed ID: 24530475
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of heat shock protein (Hsp) 90 potentiates the antiproliferative and pro-apoptotic effects of 2-(4'fluoro-phenylamino)-4H-1,3-thiazine[6,5-b]indole in A2780cis cells.
Solárová Z; Kello M; Varinská L; Budovská M; Solár P
Biomed Pharmacother; 2017 Jan; 85():463-471. PubMed ID: 27887849
[TBL] [Abstract][Full Text] [Related]
11. IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells.
Patterson J; Palombella VJ; Fritz C; Normant E
Cancer Chemother Pharmacol; 2008 May; 61(6):923-32. PubMed ID: 17624530
[TBL] [Abstract][Full Text] [Related]
12. Dynamic proteomics for investigating the response of individual cancer cells under drug action.
Li RX; Zeng R
Expert Rev Proteomics; 2009 Feb; 6(1):19-21. PubMed ID: 19210123
[TBL] [Abstract][Full Text] [Related]
13. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells.
Massey AJ; Williamson DS; Browne H; Murray JB; Dokurno P; Shaw T; Macias AT; Daniels Z; Geoffroy S; Dopson M; Lavan P; Matassova N; Francis GL; Graham CJ; Parsons R; Wang Y; Padfield A; Comer M; Drysdale MJ; Wood M
Cancer Chemother Pharmacol; 2010 Aug; 66(3):535-45. PubMed ID: 20012863
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of chemotherapeutics by the Hsp90 antagonist geldanamycin requires a steady serum condition.
Burkitt M; Magee C; O'Connor D; Campbell F; Cornford P; Greenhalf W
Mol Carcinog; 2007 Jun; 46(6):466-75. PubMed ID: 17219417
[TBL] [Abstract][Full Text] [Related]
15. Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC).
Jeong CH; Park HB; Jang WJ; Jung SH; Seo YH
Bioorg Med Chem Lett; 2014 Jan; 24(1):224-7. PubMed ID: 24345447
[TBL] [Abstract][Full Text] [Related]
16. Regulating the cytoprotective response in cancer cells using simultaneous inhibition of Hsp90 and Hsp70.
Wang Y; McAlpine SR
Org Biomol Chem; 2015 Feb; 13(7):2108-16. PubMed ID: 25526223
[TBL] [Abstract][Full Text] [Related]
17. Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective.
Kumalo HM; Bhakat S; Soliman ME
Chem Biol Drug Des; 2015 Nov; 86(5):1131-60. PubMed ID: 25958815
[TBL] [Abstract][Full Text] [Related]
18. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
[TBL] [Abstract][Full Text] [Related]
19. The combination of Hsp90 inhibitor 17AAG and heavy-ion irradiation provides effective tumor control in human lung cancer cells.
Hirakawa H; Fujisawa H; Masaoka A; Noguchi M; Hirayama R; Takahashi M; Fujimori A; Okayasu R
Cancer Med; 2015 Mar; 4(3):426-36. PubMed ID: 25582113
[TBL] [Abstract][Full Text] [Related]
20. Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
J Clin Endocrinol Metab; 2015 Feb; 100(2):E253-61. PubMed ID: 25389633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
